FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma By Ogkologos - July 22, 2026 86 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-022 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Mylan Recalls Injectable Cancer Drug After Particulates Discovered March 20, 2019 Atezolizumab Plus Bevacizumab Approved to Treat Liver Cancer June 4, 2020 A vision for the next decade of UK life sciences July 21, 2021 Classmates Surprise Badly Bullied Teen After Weeks Of Planning: ‘You Deserve... March 29, 2019 Load more HOT NEWS 3D-Printed Surgical Guides Are Helping Surgeons Save More Breast Tissue While... Mom with Breast Cancer Who Had A Year to Live Goes... Biomarkers of Pro-Inflammatory Response May Identifiy Cancer Patients at Risk of... Breast Cancer Warrior’s Emotional Photoshoot Features Her Husband Shaving Her Head
